MECHELEN, BELGIUM -- 06/30/08 --
Mechelen, Belgium; 30 June 2008 - Galapagos NV (Euronext: GLPG)
announces today that its service division BioFocus DPI will provide
compound management and related services to Sepracor Inc. (NASDAQ: SEPR), a leader in respiratory and central nervous system disorder
medicines. Total contract value for Galapagos is EUR 1 million ($1.5
million). Under the terms of the agreement, BioFocus DPI will
receive, register, and store selected compounds from Sepracor's
proprietary compound library, and plate and replicate these compounds
for a period of three years. Services will be provided by BioFocus
DPI's compound management facility in South San Francisco, USA.
"We welcome Sepracor as a new client to BioFocus DPI," said Onno van
de Stolpe, Chief Executive Officer of Galapagos. "Our compound
management site has been able to broaden its customer base over the
last year, and with this agreement we further expand our list of
pharma companies."
About BioFocus DPI compound management
BioFocus DPI provides compound management services at its South San
Francisco (USA) site, home to the National Institutes of Health
Molecular Libraries Small Molecule Repository. BioFocus DPI offers
the following compound management services: selection and sourcing,
analysis, storage, plating and reformatting, purification,
distribution. It employs state of the art equipment and compound
handling techniques to ensure sample integrity. Customers include
the government institutes NIH and Environmental Protection Agency as
well as a number of biotech and pharmaceutical companies.
About Galapagos
Galapagos (Euronext Brussels: GLPG; Euronext Amsterdam: GLPGA; OTC:
GLPYY) is a drug discovery company with pre-clinical programs in bone
and joint diseases and bone metastasis. Its BioFocus DPI division
offers a full suite of target-to-drug discovery products and services
to pharmaceutical and biotech companies, encompassing target
discovery and validation, screening and drug discovery through to
delivery of pre-clinical candidates. BioFocus DPI also provides
adenoviral reagents for rapid identification and validation of novel
drug targets, compound libraries for drug screening as well as
chemogenomics and ADMET database products to select targets and
compounds. Galapagos currently employs 460 people and operates
facilities in six countries, with global headquarters in Mechelen,
Belgium. More information about Galapagos and BioFocus DPI can be
found at www.glpg.com and www.biofocusdpi.com.
CONTACT
Galapagos NV
Onno van de Stolpe, CEO
Tel: +31 6 2909 8028
ir@glpg.com
This release may contain forward-looking statements, including,
without limitation, statements containing the words "believes,"
"anticipates," "expects," "intends," "plans," "seeks," "estimates,"
"may," "will," "could," "stands to," and "continues," as well as
similar expressions. Such forward-looking statements may involve
known and unknown risks, uncertainties and other factors which might
cause the actual results, financial condition, performance or
achievements of Galapagos, or industry results, to be materially
different from any historic or future results, financial conditions,
performance or achievements expressed or implied by such
forward-looking statements. Given these uncertainties, the reader is
advised not to place any undue reliance on such forward-looking
statements. These forward-looking statements speak only as of the
date of publication of this document. Galapagos expressly disclaims
any obligation to update any such forward-looking statements in this
document to reflect any change in its expectations with regard
thereto or any change in events, conditions or circumstances on which
any such statement is based, unless required by law or regulation.
Copyright © Hugin AS 2008. All rights reserved.
